CA2265485C - Small and intermediate conductance, calcium-activated potassium channels and uses thereof - Google Patents

Small and intermediate conductance, calcium-activated potassium channels and uses thereof Download PDF

Info

Publication number
CA2265485C
CA2265485C CA002265485A CA2265485A CA2265485C CA 2265485 C CA2265485 C CA 2265485C CA 002265485 A CA002265485 A CA 002265485A CA 2265485 A CA2265485 A CA 2265485A CA 2265485 C CA2265485 C CA 2265485C
Authority
CA
Canada
Prior art keywords
seq
amino acid
protein
calcium
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002265485A
Other languages
English (en)
French (fr)
Other versions
CA2265485A1 (en
Inventor
John P. Adelman
James Maylie
Chris T. Bond
Christopher P. Silvia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health & Science University
Icagen Inc
Original Assignee
Oregon Health & Science University
Icagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health & Science University, Icagen Inc filed Critical Oregon Health & Science University
Publication of CA2265485A1 publication Critical patent/CA2265485A1/en
Application granted granted Critical
Publication of CA2265485C publication Critical patent/CA2265485C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
CA002265485A 1996-09-11 1997-09-10 Small and intermediate conductance, calcium-activated potassium channels and uses thereof Expired - Fee Related CA2265485C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US2645196P 1996-09-11 1996-09-11
US4005297P 1997-03-07 1997-03-07
US4523397P 1997-04-17 1997-04-17
US60/045,233 1997-04-17
US60/026,451 1997-04-17
US60/040,052 1997-04-17
PCT/US1997/016033 WO1998011139A1 (en) 1996-09-11 1997-09-10 Small and intermediate conductance, calcium-activated potassium channels and uses thereof

Publications (2)

Publication Number Publication Date
CA2265485A1 CA2265485A1 (en) 1998-03-19
CA2265485C true CA2265485C (en) 2006-08-01

Family

ID=27362774

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002265485A Expired - Fee Related CA2265485C (en) 1996-09-11 1997-09-10 Small and intermediate conductance, calcium-activated potassium channels and uses thereof

Country Status (8)

Country Link
US (9) US6797486B2 (enExample)
EP (1) EP0948542B1 (enExample)
JP (5) JP4052525B2 (enExample)
AT (1) ATE366260T1 (enExample)
AU (1) AU726158B2 (enExample)
CA (1) CA2265485C (enExample)
DE (2) DE69739956D1 (enExample)
WO (1) WO1998011139A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1012281B1 (en) * 1997-07-15 2006-11-29 AstraZeneca UK Limited Human leukocyte calcium activated potassium channel polypeptide
US6165719A (en) * 1997-07-15 2000-12-26 The Regents Of The University Of California hKCa3/KCNN3 small conductance calcium activated potassium channel: a diagnostic marker and therapeutic target
AU2001265384A1 (en) 2000-06-06 2001-12-17 Millennium Pharmaceuticals, Inc. 52906, 33408, and 12189, potassium channel family members and uses thereof
EP1345618B1 (de) * 2000-12-28 2005-03-23 Switch Biotech Aktiengesellschaft Chlorzoxazon zur behandlung von psoriasis
US7022480B1 (en) * 2001-10-11 2006-04-04 The Regents Of The University Of California Exons of the hSKCa3/KCNN3 gene
US20050250090A1 (en) * 2003-10-28 2005-11-10 Edward Kaftan Assay systems and methods for detecting molecules that interact with SK2 channels
EP1884774A1 (en) * 2006-08-03 2008-02-06 INSERM (Institut National de la Santé et de la Recherche Medicale) A method for the in vitro screening of anti-cancer compounds that inhibits SK3 activity, and said anti-cancer compounds
CN110378549B (zh) * 2019-05-31 2023-05-23 广东工业大学 一种基于fahp-熵权法的输电杆塔鸟害等级评估方法
CN121057823A (zh) * 2023-04-10 2025-12-02 耶鲁大学 体内修饰神经元以治疗和/或预防肌萎缩性侧索硬化(als)的方法
WO2025175135A1 (en) * 2024-02-15 2025-08-21 Yale University Modifying neurons to treat or prevent parkinson's disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT392957B (de) 1987-08-06 1991-07-25 Technoagrar Consulting Ag Verfahren zur behandlung und entsorgung von gemengen aus feststoffen und fluessigkeiten
US6307030B1 (en) * 1988-04-15 2001-10-23 The University Of North Carolina At Chapel Hill Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions
CA2116280A1 (en) * 1993-03-05 1994-09-06 Marcy E. Macdonald Huntingtin dna, protein and uses thereof
US5519003A (en) 1994-02-01 1996-05-21 Board Of Trustees Of The Leland Stanford Junior University WD-40-derived peptides and uses thereof
US6277978B1 (en) * 1995-12-22 2001-08-21 University Of Utah Research Foundation KVLQT1—a long QT syndrome gene
EP1012281B1 (en) 1997-07-15 2006-11-29 AstraZeneca UK Limited Human leukocyte calcium activated potassium channel polypeptide
US6165719A (en) * 1997-07-15 2000-12-26 The Regents Of The University Of California hKCa3/KCNN3 small conductance calcium activated potassium channel: a diagnostic marker and therapeutic target
WO1999025347A2 (en) 1997-11-14 1999-05-27 Neurosearch A/S Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction

Also Published As

Publication number Publication date
US6828420B2 (en) 2004-12-07
US6828122B2 (en) 2004-12-07
EP0948542B1 (en) 2007-07-04
JP2004024268A (ja) 2004-01-29
DE69737889D1 (de) 2007-08-16
AU4266097A (en) 1998-04-02
JP2006320333A (ja) 2006-11-30
AU726158B2 (en) 2000-11-02
CA2265485A1 (en) 1998-03-19
EP0948542A4 (en) 2004-04-14
US7026451B2 (en) 2006-04-11
DE69737889T2 (de) 2008-03-13
US20020155531A1 (en) 2002-10-24
WO1998011139A1 (en) 1998-03-19
US20020165379A1 (en) 2002-11-07
US20030082684A1 (en) 2003-05-01
US20030082683A1 (en) 2003-05-01
JP4052525B2 (ja) 2008-02-27
US7534869B2 (en) 2009-05-19
US20050214845A1 (en) 2005-09-29
US20030105284A1 (en) 2003-06-05
US6894147B2 (en) 2005-05-17
EP0948542A1 (en) 1999-10-13
US6828123B2 (en) 2004-12-07
JP2008092950A (ja) 2008-04-24
US6987169B2 (en) 2006-01-17
JP4052582B2 (ja) 2008-02-27
JP2000514310A (ja) 2000-10-31
US20020192757A1 (en) 2002-12-19
US6692937B2 (en) 2004-02-17
US20030044910A1 (en) 2003-03-06
DE69739956D1 (de) 2010-09-16
JP2004065264A (ja) 2004-03-04
US20030040048A1 (en) 2003-02-27
ATE366260T1 (de) 2007-07-15
US6797486B2 (en) 2004-09-28

Similar Documents

Publication Publication Date Title
JP2008092950A (ja) 低及び中間コンダクタンスのカルシウム活性化されたカリウムチャネル及びその使用
JP2004537954A (ja) ナイセリア・メニンギティディス・ポリペプチドｂａｓｂ０５２
US20100203057A1 (en) Novel compounds
CA2360658A1 (en) Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
EP1112366B1 (en) Polynucleotides and polypeptides basb033 from neisseria meningitidis and their uses
PT1163343E (pt) Polipéptidos antigénicos de neisseria meningitidis, polinucleótidos e anticorpos protectores correspondentes
US6770284B1 (en) Polypeptides and polynucleotides BASB040 from neisseria meningitidis and vaccine comprising said polypeptides and polynucleotides
EP1892252B1 (en) Intermediate conductance, calcium-activated potassium channels and uses thereof
US20050075485A1 (en) Neisseria meningitidis antigen
EP2374889A2 (en) Novel compounds
JP2004537955A (ja) ナイセリア・メニンギティディス由来のｂａｓｂ０５５ポリヌクレオチド及びポリペプチド、その使用
HK1038041B (en) Polynucleotides and polypeptides basb033 from neisseria meningitidis and their uses

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140910